Science and Research

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab

BACKGROUND: PERLA (NCT04581824) compared efficacy and safety of dostarlimab (DCT) or pembrolizumab (PCT) plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer. Here, we report patient-reported outcomes (PROs; exploratory analysis) from PERLA. METHODS: Patients were randomized 1:1 to receive DCT or PCT every 3 weeks (Q3W) for

  • Reck, M.
  • Granados, A. L. O.
  • de Marinis, F.
  • Meyers, O.
  • Shen, Q.
  • Cho, L.
  • Stjepanovic, N.
  • Boklage, S.

Keywords

  • Dostarlimab
  • Health-related quality of life
  • Non-small cell lung cancer
  • Patient-reported outcomes
  • Pembrolizumab
Publication details
DOI: 10.1016/j.ejca.2024.115050
Journal: Eur J Cancer
Pages: 115050 
Work Type: Original
Location: ARCN
Disease Area: LC
Partner / Member: Ghd
Access-Number: 39378565

DZL Engagements

chevron-down